<code id='E1735AA39B'></code><style id='E1735AA39B'></style>
    • <acronym id='E1735AA39B'></acronym>
      <center id='E1735AA39B'><center id='E1735AA39B'><tfoot id='E1735AA39B'></tfoot></center><abbr id='E1735AA39B'><dir id='E1735AA39B'><tfoot id='E1735AA39B'></tfoot><noframes id='E1735AA39B'>

    • <optgroup id='E1735AA39B'><strike id='E1735AA39B'><sup id='E1735AA39B'></sup></strike><code id='E1735AA39B'></code></optgroup>
        1. <b id='E1735AA39B'><label id='E1735AA39B'><select id='E1735AA39B'><dt id='E1735AA39B'><span id='E1735AA39B'></span></dt></select></label></b><u id='E1735AA39B'></u>
          <i id='E1735AA39B'><strike id='E1735AA39B'><tt id='E1735AA39B'><pre id='E1735AA39B'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:58
          A stethoscope lays on banknotes next to a calculator, all on top of a insurance application form — coverage from STAT
          Adobe

          Major insurance companies like UnitedHealthcare and Humana have edged out private equity firms from investing in Medicare Advantage, according to a new report.

          But investors have found pockets of profits by backing companies involved in enrolling seniors in MA plans and keeping track of them once they’re there. They’re investing in insurance brokerages, marketers, in-home assessment companies, and “insurtechs,” the report said, based on a new analysis of deals in the space since 2016.

          advertisement

          Overall, private equity investors made only 4 investments in Medicare Advantage-related companies last year, compared with 12 in 2022, down from a peak of 19 in 2021, per the Private Equity Stakeholder Project, a group focused on holding private equity firms accountable for their impacts on people and the planet, according to its website.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?
          ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

          SusanGalbraith,AstraZeneca’sheadofcancerresearchanddevelopment,speaksataSTATeventin2023.MarieMillerf

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

          ANDREWYATES/AFPviaGettyImagesInpatientswithstage3lungcancerwhereaparticulargeneticmutationispresenti